Hepatitis C Virus: Efficacy of New DAAs Regimens.
DAA
Direct-acting antivirals
HCV therapy
HCV treatment
interferon
sofosbuvir.
Journal
Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
12
2018
revised:
11
01
2019
accepted:
14
01
2019
pubmed:
22
1
2019
medline:
15
12
2020
entrez:
22
1
2019
Statut:
ppublish
Résumé
HCV treatment showed dramatical change due to the introduction of potent, strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple therapeutic interventions were used for hepatitis C, but none of these interventions were effective on patient-centered outcomes. Direct-acting antivirals cause disruption of viral replication because they target specific nonstructural viral proteins. To review the advantages of efficient HCV therapy and its long term drawbacks. A search of the literature published in indexed databases (PubMed, Medline In-Process, and Embase) within the last 5 years was conducted. Any duplicated citations were excluded before first-pass screening. Citations (titles and abstracts) were screened for eligibility by a single reviewer. Full texts (including congress abstracts, posters and other congress communications) of citations deemed relevant during title and abstract screening were retrieved for second-pass review. Studies on the clinical effects of DAAs for hepatitis C show better tolerance, improved survival and fewer complications when compared to previous interferon therapy. HCV treatment has improved dramatically. Since that time, there are multiple approved oral therapies all with high efficacy. The most important factor which should be considered during choosing appropriate therapy is to ensure that it covers the viral genotype of the infected patients.
Sections du résumé
BACKGROUND
BACKGROUND
HCV treatment showed dramatical change due to the introduction of potent, strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple therapeutic interventions were used for hepatitis C, but none of these interventions were effective on patient-centered outcomes. Direct-acting antivirals cause disruption of viral replication because they target specific nonstructural viral proteins.
AIM
OBJECTIVE
To review the advantages of efficient HCV therapy and its long term drawbacks.
METHODS
METHODS
A search of the literature published in indexed databases (PubMed, Medline In-Process, and Embase) within the last 5 years was conducted. Any duplicated citations were excluded before first-pass screening. Citations (titles and abstracts) were screened for eligibility by a single reviewer. Full texts (including congress abstracts, posters and other congress communications) of citations deemed relevant during title and abstract screening were retrieved for second-pass review.
RESULTS
RESULTS
Studies on the clinical effects of DAAs for hepatitis C show better tolerance, improved survival and fewer complications when compared to previous interferon therapy.
CONCLUSION
CONCLUSIONS
HCV treatment has improved dramatically. Since that time, there are multiple approved oral therapies all with high efficacy. The most important factor which should be considered during choosing appropriate therapy is to ensure that it covers the viral genotype of the infected patients.
Identifiants
pubmed: 30663575
pii: IDDT-EPUB-95967
doi: 10.2174/1871526519666190121114003
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-149Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.